Penpulimab, anlotinib, and chemo before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (penpulimab, anlotinib, and chemotherapy) given before surgery to shrink esophageal cancer. It is for people with locally advanced cancer who have not had treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have esophageal cancer that has not spread to distant organs (stage II to IVA).
- You have not had any previous treatment for your esophageal cancer.
- You are in good enough health to be active (ECOG score 0 or 1).
- Your major organs (heart, lungs, liver, kidneys, bone marrow, thyroid) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial tests a combination of targeted therapy (anlotinib), immunotherapy (toripalimab), and chemotherapy given before surgery for esophageal cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy given before and after surgery for esophageal cancer. It aims to see if this approach can improve treatment outcomes for patients with a certain stage of the disease.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.